Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 3/20 | 0.48 |
| ▸ | CTSL | P07711 | 9/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.45 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL823239 | 0.82 | TLR7 (0.50) | CTSLADORA2AADORA1TMIGD3ADORA2B | |
| SCHEMBL823232 | 0.78 | ADORA2A (0.47) | ADORA2AADORA1TMIGD3ADORA2B | |
| SCHEMBL2913215 | 0.71 | ADORA2A (0.67) | ADORA2AADORA1TMIGD3ADORA2BMAPK1 | |
| SCHEMBL823178 | 0.71 | TLR7 (0.50) | CTSL | |
| SCHEMBL7939004 | 0.69 | APP (0.68) | CDK1PDE5AAPP | |
| SCHEMBL7208425 | 0.69 | ADORA2A (0.76) | ADORA2AADORA1TMIGD3ADORA2BAPP | |
| SCHEMBL14944655 | 0.67 | ADORA2A (0.61) | CTSLADORA2AADORA1TMIGD3ADORA2B | |
| SCHEMBL20350685 | 0.66 | CDK1 (0.73) | CDK1CTSLADORA2AADORA1TMIGD3 | |
| SCHEMBL5132410 | 0.66 | ADORA2A (0.67) | CDK1ADORA2AADORA1TMIGD3ADORA2B | |
| SCHEMBL24600679 | 0.66 | CDK1 (0.73) | CDK1CTSLADORA2AADORA1TMIGD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | CDK1 1061/4885CTSL 4404/4885ADORA2A 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.